WO2023017446A1 - Novel plk1 degradation inducing compound - Google Patents

Novel plk1 degradation inducing compound Download PDF

Info

Publication number
WO2023017446A1
WO2023017446A1 PCT/IB2022/057475 IB2022057475W WO2023017446A1 WO 2023017446 A1 WO2023017446 A1 WO 2023017446A1 IB 2022057475 W IB2022057475 W IB 2022057475W WO 2023017446 A1 WO2023017446 A1 WO 2023017446A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ring
dioxopiperidin
cancer
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/057475
Other languages
English (en)
French (fr)
Inventor
Soo Hee RYU
Im Suk MIN
Han Kyu Lee
Seong Hoon Kim
Hye Guk Ryu
Keum Young KANG
Sang Youn Kim
So Hyun Chung
Jun Kyu Lee
Gibbeum Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uppthera Inc
Original Assignee
Uppthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uppthera Inc filed Critical Uppthera Inc
Publication of WO2023017446A1 publication Critical patent/WO2023017446A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. It can specifically act on abnormal cells, etc. and can be usefully used in the treatment of various diseases through efficient degradation of PLK1.
  • Polo-like kinase 1 is a serine/threonine kinase involved in the conversion of G2/M phase during cell growth and division. PLK1 is expressed and activated in a pulse form from the S phase to the G2/M phase, and rapidly degrades as mitosis ends.
  • PLK1 is overexpressed in various carcinomas such as colon cancer, lung cancer, bladder cancer, and melanoma, etc., and cancer cells overexpressing PLK1 tend to show resistance to various types of anticancer drugs.
  • PLK1 inhibitor compounds such as volasertib (also known as BI6727), etc.
  • the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
  • the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
  • many pharmaceutical companies such as Boehringer Ingelheim, GlaxoSmithKline, etc., have attempted to develop small-molecular compound-based PLK1 inhibitors, but most of them have failed or stopped in the clinical trial stage, and thus there are no commercially available PLK1 inhibitors to date.
  • PROTAC proteolysis targeting chimera
  • the PROTAC is a bifunctional compound in which a ligand molecule that binds to disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker.
  • the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase. Based on this new mechanism different from the existing inhibitors, a lot of PROTAC compounds have been developed as therapeutic agents for cancer and inflammatory diseases, etc., and being studied with various extensibility (e.g.
  • the PROTAC compound described in the above-described document is characterized by a compound that simultaneously degrades PLK1 and BRD4, and degrade various proteins such as other PLK family proteins and BRD4, etc.), which may cause side effects due to off-target toxicities at the time of drug development.
  • a compound that simultaneously degrades PLK1 and BRD4 and degrade various proteins such as other PLK family proteins and BRD4, etc.
  • BRD4 activity inevitably accompanies on-target toxicity such as blood toxicity and gastrointestinal toxicity along with pharmacological effects. Therefore, the PROTAC compound described in the above document would expect to face greater clinical side effects as more BRD4 protein gets degraded (see Bolden et al. Cell Reports, 2014).
  • the PROTAC compound which simultaneously degrades PLK1 and BRD4, has much stronger BRD4 degradation ability than PLK1 degradation ability at the cellular level, and the cell cycle thereof almost stops in the G1 phase, etc., that is, the PROTAC compound actually acts only as a BRD4 inhibitor regardless of the way that the conventional PLK1 inhibitors exert pharmacological effects.
  • An object of the present disclosure is to provide novel PLK1 degradation inducing compounds.
  • Another object of the present disclosure is to provide a method for preparing the compounds.
  • Still another object of the present disclosure is to provide a use of the compounds.
  • novel PROTAC compounds of the present invention specifically act on abnormal cells overexpressing PLK1 through appropriate structural combination and optimization of E3 Ligase binder, Target binding moiety, and Linker to induce effective PLK1 degradation and minimize side effects, and completed the present invention.
  • the present disclosure provides novel compounds that induce effective polo-like kinase 1 (PLK1) degradation.
  • PLK1 polo-like kinase 1
  • the present disclosure provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker.
  • ULM is a moiety represented by the following Formula 1a;
  • PTM is a moiety represented by the following Formula 2a;
  • Linker is a group that chemically links ULM and PTM;
  • R U is -H or -halo
  • R 1 is -C 1-4 alkyl or 3- to 7-membered cycloalkyl
  • R 2 is -H
  • R 3 and R 4 are each independently -H, -C 1-4 alkyl, -C 1-4 alkenyl or -halo, or R 3 and R 4 are linked each other to form a 3- to 6-membered ring;
  • R 5 is -C 1-4 alkyl
  • R 6 is -C 1-4 alkyl, -C 1-4 haloalkyl, -O-R P or -halo;
  • R 7 is -H, -C 1-4 alkyl, -C 1-4 haloalkyl, -halo or 5- to 6-membered heterocycloalkyl ⁇ wherein at least one H of the 5- to 6-membered heterocycloalkyl ring may be substituted with -C 1-4 alkyl ⁇ , or is linked with the Linker to form a 5- to 6-membered ring; and
  • R P is -H, -C 1-4 alkyl, -C 1-4 hydroxyalkyl or -C 1-4 haloalkyl.
  • ULM is a moiety represented by the following Formula 1a-1 or Formula 1a-2;
  • R U is -H or -halo.
  • ULM is , , , or ;
  • R U is -H or -halo.
  • PTM is ;
  • R 1 is -isopropyl, -cyclopropyl, -cyclobutyl or -cyclopentyl;
  • R 3 and R 4 are each independently -H, -C 1-4 alkyl, -C 1-4 alkenyl or -halo, or R 3 and R 4 are linked each other to form a 3-membered ring;
  • R 6 is -C 1-4 alkyl, -C 1-4 haloalkyl, -O-R P or -halo;
  • R 7 is -H, -C 1-4 haloalkyl, -halo or 5- to 6-membered heterocycloalkyl ⁇ wherein at least one H of the 5- to 6-membered heterocycloalkyl ring may be substituted with -C 1-4 alkyl ⁇ , or is linked with the Linker to form a 5- to 6-membered heterocycloalkyl ring; and
  • R P is -H, -C 1-4 alkyl, -C 1-4 hydroxyalkyl or -C 1-4 haloalkyl.
  • Linker is -L U -L 1 -L 2 -L 3 -L P -;
  • L U is -(CH 2 )x-, -C ⁇ C-, -NH-, -O-, -S- or nothing (null) ⁇ wherein L U is linked with ULM [wherein, when the L U is nothing (null), L 1 is directly linked with ULM], and the x is 0, 1, 2, 3 or 4 ⁇ ;
  • L 3 is cycloalkyl, heterocycloalkyl, phenyl or nothing (null) ⁇ wherein, when the L 3 is nothing (null), L 2 and L p are directly linked, the heterocycloalkyl contains at least one N atom in the ring, and at least one H of the cycloalkyl, heterocycloalkyl or phenyl ring may be substituted with -C 1-4 alkyl, -C 1-4 haloalkyl or -halo ⁇ ;
  • R L is -H or -C 1-4 alkyl.
  • L U is -(CH 2 )x-, -C ⁇ C-, -NH-, -O-, -S- or nothing (null) ⁇ wherein L U is linked with ULM [wherein, when the L U is nothing (null), L 1 is directly linked with ULM], and the x is 0 or 1 ⁇ ;
  • L 1 is 4- to 12-membered heterocycloalkyl or nothing (null) ⁇ wherein, when the L 1 is nothing (null), L U and L 2 are directly linked, the 4- to 12-membered heterocycloalkyl is single ring, bridged bicyclic ring or spiro ring, the 4- to 12-membered heterocycloalkyl contains at least one N atom in the ring, and at least one H of the 4- to 12-membered heterocycloalkyl ring may be substituted with -OH or -halo ⁇ ;
  • L 3 is 4- to 6-membered cycloalkyl, 4- to 12-membered heterocycloalkyl, phenyl or nothing (null) ⁇ wherein, when the L 3 is nothing (null), L 2 and Lp are directly linked, the 4- to 12-membered heterocycloalkyl is single ring, bridged bicyclic ring or spiro ring, the 4- to 12-membered heterocycloalkyl contains at least one N atom in the ring, and at least one H of the 4- to 6-membered cycloalkyl, 4- to 12-membered heterocycloalkyl or phenyl ring may be substituted with -halo ⁇ ;
  • R L is -H or -C 1-4 alkyl.
  • ULM is a moiety represented by the following Formula 1b;
  • PTM is a moiety represented by the following Formula 2b;
  • Linker is a group that chemically links ULM and PTM;
  • X 1 and X 2 are each independently CHR X , CR X or N;
  • R X is -H or -C 1-4 alkyl
  • ring U is phenyl or 5- to 6-membered heteroaryl ⁇ wherein, when the V is nothing (null), ring U is directly linked with X 1 or X 2 , and at least one H of the phenyl or 5- to 6-membered heteroaryl ring may be substituted with R U ⁇ ;
  • Y is CR 7 or N
  • R 1 is -C 1-4 alkyl or 3- to 7-membered cycloalkyl
  • R 2 is -H or -C 1-4 alkyl, or is linked with R 1 to form a 5- to 6-membered ring together with N atom;
  • R 3 and R 4 are each independently -H, -C 1-4 alkyl or -halo, or R 3 and R 4 are linked each other to form a 3- to 6-membered ring;
  • R 5 is -C 1-4 alkyl
  • R 6 is -C 1-4 alkyl, -C 1-4 hydroxyalkyl, -C 1-4 aminoalkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo;
  • R 7 is -H or -halo.
  • ULM is a moiety represented by the following Formula 1b-1;
  • X 1 and X 2 are each independently CH 2 , CH or N;
  • ring U is phenyl or 5- to 6-membered heteroaryl linked with the X 1 or X 2 ⁇ wherein at least one H of the phenyl or 5- to 6-membered heteroaryl ring may be substituted with R U ⁇ ;
  • R U is -C 1-4 alkyl, -C 1-4 hydroxyalkyl, -C 1-4 aminoalkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo.
  • ULM is a moiety represented by following Formula 1;
  • X 1 and X 2 are each independently CH 2 , CH or N;
  • ring U is phenyl, pyridinyl, pyrimidinyl or pyrazolyl linked to the X 1 or X 2 ⁇ wherein at least one H of the phenyl, pyridinyl, pyrimidinyl or pyrazolyl ring may be substituted with R U ⁇ ; and
  • R U is -C 1-4 alkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo.
  • ULM is a moiety represented by the following Formula 1b-2;
  • X 1 is CH or N
  • ring U is phenyl or 5- to 6-membered heteroaryl ⁇ wherein at least one H of the phenyl or 5- to 6-membered heteroaryl ring may be substituted with R U ⁇ ;
  • R U is -C 1-4 alkyl, -C 1-4 hydroxyalkyl, -C 1-4 aminoalkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo.
  • ULM is a moiety represented by following Formula 1-1 or Formula 1-2;
  • ring U is phenyl, pyridinyl, pyrimidinyl or pyrazolyl ⁇ wherein at least one H of the phenyl, pyridinyl, pyrimidinyl or pyrazolyl ring may be substituted with R U ⁇ ;
  • R U is -C 1-4 alkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo.
  • ULM is , , , , , , , , , , , , , , , , , , , or ;
  • R U1 and R U2 are each independently -C 1-4 alkyl, -C 1-4 haloalkyl, -C 1-4 alkoxy or -halo.
  • ULM is a moiety represented by the following Formula 1b-3;
  • R X is -H or -C 1-4 alkyl
  • ring U is phenyl, pyridinyl or pyrimidinyl ⁇ wherein at least one H of the phenyl, pyridinyl or pyrimidinyl ring may be substituted with R U ⁇ ;
  • ULM is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ;
  • R U1 and R U2 are each independently -C 1-4 alkyl, -C 1-4 haloalkyl or -halo.
  • PTM is , , , or ;
  • Y is CH, CF or N
  • R 6 is -C 1-4 alkyl, -C 1-4 alkoxy or -halo.
  • Linker is -L U -L 1 -L 2 -L 3 -L P -;
  • L 3 is cycloalkyl, heterocycloalkyl or nothing (null) ⁇ wherein, when the L 3 is nothing (null), L 2 and L p are directly linked, the heterocycloalkyl contains at least one N atom in the ring, and at least one H of the cycloalkyl or heterocycloalkyl may be substituted with -C 1-4 alkyl, -C 1-4 haloalkyl or -halo ⁇ ; and
  • L 3 is 4- to 6-membered cycloalkyl, 4- to 12-membered heterocycloalkyl or nothing (null) ⁇ wherein, when the L 3 is nothing (null), L 2 and L p are directly linked, the 4- to 12-membered heterocycloalkyl is single ring, bridged bicyclic ring or spiro ring, the 4- to 12-membered heterocycloalkyl contains at least one N atom in the ring, and at least one H of the 4- to 6-membered cycloalkyl or 4- to 12-membered heterocycloalkyl ring may be substituted with -C 1-4 alkyl, -C 1-4 haloalkyl or -halo ⁇ ; and
  • the compound represented by Formula Ia is a compound that is selected from the group consisting of Compounds A-1 to A- 225 of the table 1, Compounds B-1 to B-59 of the table 2, Compounds C-1 to C-46 of the table 3, and Compounds D-1 to D- 44 of the table 4.
  • a pharmaceutically acceptable salt refers to any organic or inorganic acid addition salt with a concentration that is relatively non-toxic, is harmless, and has effective action to patients, wherein side effects caused by this salt does not deteriorate beneficial efficacy of the compound represented by Formula I.
  • the pharmaceutically acceptable salt may be an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like, or an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid, but is not limited thereto.
  • an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like
  • an organic acid such as methanesulfonic acid, p-toluenesulf
  • An embodiment of the present disclosure is a composition for inducing PLK1 degradation including a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
  • the Formula I is the same as defined above.
  • the PLK1 degradation-inducing PROTAC compound of the present disclosure is capable of fundamentally degrading the target protein, PLK1 in view of the mechanism of action, thereby achieving an excellent PLK1 inhibitory effect as compared to the conventional PLK1 small molecule inhibitor that inhibits the simple activity of PLK1.
  • composition including the compound represented by Formula I of the present disclosure or a pharmaceutically acceptable salt thereof may be effectively employed for selective degradation of PLK1.
  • An embodiment of the present disclosure is a composition for preventing or treating PLK1-related diseases including the compound represented by Formula I or the pharmaceutically acceptable salt thereof.
  • An another embodiment of the present disclosure is a method for the preventon or treatment of PLK-related diseases comprising administering the composition to a subject in need thereof.
  • the Formula I is the same as defined above.
  • the PLK1-related disease refers to any disease or condition capable of being treated, alleviated, delayed, inhibited or prevented from induction of degradation or inhibition of activity of PLK1.
  • the PLK1-related disease may be a cancer (malignant tumor), a benign tumor, a neurological disease, or other genetic or non-genetic diseases caused by excessive cell division.
  • the cancer includes all cancers capable of exhibiting prophylactic or therapeutic efficacy due to inhibition of PLK1 activity, and may be solid cancer or blood cancer.
  • the cancer may be one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, skin cancer, skin or intraocular melanoma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer,
  • the benign tumors include all benign tumors capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, such as benign tumors in pre-cancer stages, and may be solid tumors or blood tumors.
  • the tumor may be one or more selected from the group consisting of Barrett's esophagus, colon adenoma and polyp, breast fibroadenoma and cyst, monoclonal gammopathy of undetermined significance (MGUS), monoclonal lymphocytosis, and the like, but is not limited thereto.
  • the neurological diseases include all neurological diseases capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, and specifically, may be one or more selected from the group consisting of central nervous system disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, senile dementia, epilepsy, Lou Gehrig, stroke, and nerve damage and axonal degeneration-related disorders following brain or spinal cord injury, but is not limited thereto.
  • composition of the present disclosure may further include one or more active ingredients exhibiting the same or similar medicinal effects in addition to the compound represented by Formula I above, or the pharmaceutically acceptable salt thereof.
  • An embodiment of the present disclosure is a method of degrading PLK1 by administering a compound represented by Formula I or a pharmaceutically acceptable salt thereof to mammals including humans.
  • Another embodiment of the present disclosure is a method of degrading PLK1 by administering the compound represented by Formula I or the pharmaceutically acceptable salt thereof to a sample in vitro.
  • the sample may be a cell, a cell culture, a body fluid or tissue of a mammal including a human, but is not limited thereto.
  • the compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
  • Figure 1 shows the luciferase assay results by treating Compound A-1 to Compound A-49 of the present invention.
  • Figure 2 shows the luciferase assay results by treating Compound A-50 to Compound A-90 of the present invention.
  • Figure 3 shows the luciferase assay results by treating Compound A-91 to Compound A-131 of the present invention.
  • Figure 4 shows the luciferase assay results by treating Compound A-133 to Compound A-180 of the present invention.
  • Figure 5 shows the luciferase assay results by treating Compound A-182 to Compound A-225 of the present invention.
  • Figure 6 shows the luciferase assay results by treating Compound B-1 to Compound B-25 of the present invention.
  • Figure 7 shows the luciferase assay results by treating Compound B-26 to Compound B-59 of the present invention.
  • Figure 8 shows the luciferase assay results by treating Compound C-1 to Compound C-46 of the present invention.
  • Figure 9 shows the luciferase assay results by treating Compound D-1 to Compound D-41 of the present invention.
  • the present disclosure provides synthetic methods for Compound A-1 to A-225 shown in the table 1 below.
  • the present disclosure provides synthetic methods for Compound B-1 to B-59 shown in the table 2 below.
  • the present disclosure provides synthetic methods for Compound C-1 to C-46 shown in the table 3 below.
  • the present disclosure provides synthetic methods for Compound D-1 to D-44 shown in the table 1 below.
  • the compounds of the present invention were purified according to the following method and the structure was analyzed.
  • LCMS Shimadzu LCMS-2020, Agilent 1200/G6110A, Agilent 1200/G1956A
  • LCMS data were recorded with Shimadzu LCMS-2020 or Agilent 1200/G6110A or Agilent 1200/G1956A equipped with an ESI (Electron Spray Ionization) device.
  • 0.0375% TFA in water (solvent A) and 0.01875% TFA in ACN (solvent B) or 0.025% NH 3 ⁇ H 2 O in water (solvent A) and ACN (solvent B) were used as mobile phases.
  • Kinetex EVO C18 2.1 x 30 mm, 5 ⁇ m
  • HALO C18 3.0 x 30 mm, 2.7 ⁇ m
  • Chiralpak AD-3 50 x 4.6 mm, 3 ⁇ m
  • Chiralpak AS-3 50 x 4.6 mm, 3 ⁇ m
  • Chiralpak OJ-3 50 x 4.6 mm, 3 ⁇ m
  • Chiralpak IA-3 50 x 4.6 mm, 3 ⁇ m
  • Chiralpak OD 50 x 4.6 mm, 3 ⁇ m
  • Chiralpak IC-3 50 x 4.6 mm, 3 ⁇ m
  • S,S Whelk-O1
  • reaction mixture was concentrated in vacuum to remove most of the solvent.
  • the residue was diluted with H 2 O (200 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (300 mL x 5), dried over Na 2 SO 4 , filtered and concentrated in vacuum.
  • the compound 2 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 4 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 5 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 6 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 8 was synthesized by the method described in the scheme similar to the method described in Example 7.
  • the compound 9 was synthesized by the method described in the scheme similar to the method described in Example 7.
  • reaction was stirred and irradiated with a 34 W blue LED lamp (7 cm away), with cooling fan to keep the reaction temperature at 25 °C for 14 hr.
  • LCMS showed a peak (66%) with desired mass.
  • the reaction mixture was diluted with brine (20 mL), extracted with EtOAc (20 mL ⁇ 3). The combined organic layers were washed with brine (20 mL ⁇ 2), dried over Na 2 SO 4 , filtered. The filtrate was concentrated under reduced pressure to give a residue.
  • reaction mixture was diluted with H 2 O (20 mL), extracted with EtOAc (10 mL ⁇ 2). The combined organic layers were washed with brine (20 mL ⁇ 2), dried over Na 2 SO 4 , filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • the compound 16 was synthesized by the method described in the scheme similar to the method described in Example 15.
  • the compound 17 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 18 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 19 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • the compound 20 was synthesized by the method described in the scheme similar to the method described in Example 1.
  • reaction mixture was concentrated to give a residue and then H 2 O (80 mL) was added, the mixture was extracted with EtOAc 300 mL (100 mL x 3), then the combined organic layers were washed with brine (100 mL x 2), dried over Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure.
  • the mixture was purified by prep-HPLC (column: Phenomenex Synergi Polar-RP 100x25 mmx4um;mobile phase: [water (TFA) -ACN];B%: 48%-68%, 7 min) and re-purified by prep-HPLC (column: Waters Xbridge 150 x 25 mm x 5 ⁇ m; mobile phase: [water (NH 4 HCO 3 ) -ACN]; B%: 42%-72%, min) and lyophilized to afford 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperidin
  • the compound 25 was synthesized by the method described in the scheme similar to the method described in Example 24.
  • Example 26 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)-3-methoxybenzamide (Compound 26)
  • Example 27 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)-3-fluorobenzamide ( Compound 27 )
  • the compound 27 was synthesized by the method described in the scheme similar to the method described in Example 26.
  • Example 28 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)-3-(trifluoromethoxy)benzamide ( Compound 28 )
  • the reaction mixture was diluted with H 2 O (10 mL), then HCl (12 N) was added to adjust the PH ⁇ 3.
  • the suspension was concentrated in vacuum.
  • the crude product was triturated with a mixture solvent (MTBE/EtOAc (4 mL/4 mL)) at 20 °C for 0.5 h, then filtered.
  • Step 4 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-2-fluoro-5-methoxybenzamide (Compound 29)
  • the compound 31 was synthesized by the method described in the scheme similar to the method described in Example 26.
  • the compound 32 was synthesized by the method described in the scheme similar to the method described in Example 26.
  • Step 3 Synthesis of 4-((7, 7-difluoro-9-isopropyl-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-N-(1-(4-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 33)
  • the compound 34 was synthesized by the method described in the scheme similar to the method described in Example 33.
  • the compound 35 was synthesized by the method described in the scheme similar to the method described in Example 24.
  • Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)amino)butanoyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 36)
  • the reaction mixture was filtered through a celite pad.
  • the filtrate was purified by prep-HPLC (column: Phenomenex luna C18 150 x 40 mm x 15 ⁇ m; mobile phase: [water (TFA) -ACN]; B%: 22%-52%, 11 min) and lyophilized to afford tert-butyl (1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetyl)piperidin-4-yl)carbamate (0.5 g, 874.59 ⁇ mol, 47.97% yield, 90% purity) as white solid.
  • MS(M+H) + 515.2
  • Step 4 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 37)
  • Example 38 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H- pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetyl)piperidin-4-yl)-3-methoxybenzamide (Compound 38)
  • the compound 38 was synthesized by the method described in the scheme similar to the method described in Example 23.
  • the compound 39 was synthesized by the method described in the scheme similar to the method described in Example 23.
  • Example 40 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H- pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-((3S)-1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetyl)pyrrolidin-3-yl)-3-methoxybenzamide (Compound 40)
  • the compound 40 was synthesized by the method described in the scheme similar to the method described in Example 23.
  • the compound 41 was synthesized by the method described in the scheme similar to the method described in Examples 11 and 23.
  • the compound 42 was synthesized by the method described in the scheme similar to the method described in Examples 11 and 23.
  • Example 43 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-4-oxobutanoyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide ( Compound 43 )
  • Example 45 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H -pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)acetyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 45)
  • the compound 45 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • the compound 46 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • the compound 47 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • the compound 48 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • the compound 49 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • Step 3 Synthesis of a mixture of benzyl ((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)carbamate (5A) and benzyl ((1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)methyl)carbamate (5)
  • Step 4 Synthesis of 4-(4-((4-(aminomethyl)piperidin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (6A) and 4-(3-(2-(4-(aminomethyl)piperidin-1-yl)ethyl)pyrrolidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (6)
  • benzyl 3-(4-aminopiperazin-1-yl)pyrrolidine-1-carboxylate (0.2 g, 657.06 ⁇ mol) was added to the mixture after 0.5 h. The mixture was stirred at 25 °C for 2 h. LCMS showed ⁇ 45% of desired mass was detected. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue.
  • Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)piperazin-1-yl)-3-methoxybenzamide (Compound 51)
  • Example 52 Synthesis of 4-((7,7-difluoro-9-isopropyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)piperazin-1-yl)-3-methoxybenzamide ( Compound 52 )
  • Step 8 Synthesis of 4-(3-(4-aminopiperazin-1-yl)pyrrolidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione ( 10 )
  • Step 9 Synthesis of 4-((7,7-difluoro-9-isopropyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)piperazin-1-yl)-3-methoxybenzamide ( Compound 52 )
  • Example 54 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-3-yl)methyl)piperidin-4-yl)-3-methoxybenzamide (Compound 54)
  • the compound 54 was synthesized by the method described in the scheme similar to the method described in Example 50.
  • the compound 56 was synthesized by the method described in the scheme similar to the method described in Example 51.
  • reaction mixture was diluted with water (50 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue.
  • Example 58 Synthesis of 4-((7,7-difluoro-9-isopropyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)piperidin-4-yl)propanoyl)piperazin-1-yl)-3-methoxybenzamide (Compound 58)
  • tert-butyl 4-aminopiperazine-1-carboxylate (210.15 mg, 1.04 mmol) was added and the resulting mixture was stirred at 25 °C for 1 h.
  • LCMS showed a peak (61%) with desired mass.
  • the mixture solution was poured into water (40 mL) and extracted with EtOAc (20 mL x 4). The combined organic layers were dried over Na 2 SO 4 and concentrated.
  • the compound 59 was synthesized by the method described in the scheme similar to the method described in Example 58.
  • Example 60 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)propyl)piperidin-4-yl)-3-methoxybenzamide (Compound 60)
  • Example 61 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propanoyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 61)
  • the compound 61 was synthesized by the method described in the scheme similar to the method described in Example 44.
  • Example 62 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)propanoyl)piperidin-4-yl)-3-methoxybenzamide (Compound 62)
  • the compound 62 was synthesized by the method described in the scheme similar to the method described in Example 44.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/IB2022/057475 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound Ceased WO2023017446A1 (en)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
KR20210105358 2021-08-10
KR10-2021-0105358 2021-08-10
KR10-2021-0106488 2021-08-12
KR20210106488 2021-08-12
KR10-2021-0117389 2021-09-03
KR20210117389 2021-09-03
KR20210126757 2021-09-24
KR10-2021-0126757 2021-09-24
KR20220008456 2022-01-20
KR10-2022-0008456 2022-01-20
KR20220020996 2022-02-17
KR10-2022-0020996 2022-02-17
KR10-2022-0054880 2022-05-03
KR20220054880 2022-05-03
KR20220075838 2022-06-21
KR10-2022-0075838 2022-06-21

Publications (1)

Publication Number Publication Date
WO2023017446A1 true WO2023017446A1 (en) 2023-02-16

Family

ID=85200656

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2022/057475 Ceased WO2023017446A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/KR2022/011963 Ceased WO2023018238A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/KR2022/011961 Ceased WO2023018236A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/KR2022/011962 Ceased WO2023018237A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/IB2022/057471 Ceased WO2023017442A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/KR2022/011963 Ceased WO2023018238A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/KR2022/011961 Ceased WO2023018236A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/KR2022/011962 Ceased WO2023018237A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound
PCT/IB2022/057471 Ceased WO2023017442A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Country Status (15)

Country Link
US (4) US11939334B2 (enExample)
EP (4) EP4157850A4 (enExample)
JP (4) JP7555155B2 (enExample)
KR (5) KR102604802B1 (enExample)
CN (2) CN116261458B (enExample)
AU (1) AU2022327025A1 (enExample)
CA (1) CA3228601A1 (enExample)
CL (1) CL2024000373A1 (enExample)
CO (1) CO2024001256A2 (enExample)
CR (1) CR20240120A (enExample)
EC (1) ECSP24010109A (enExample)
IL (1) IL310678A (enExample)
MX (1) MX2024001774A (enExample)
PE (1) PE20240894A1 (enExample)
WO (5) WO2023017446A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230104076A1 (en) * 2020-03-27 2023-04-06 Uppthera PLK1 Selective Degradation Inducing Compound
JP2024530195A (ja) * 2021-08-10 2024-08-16 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
WO2025036285A1 (zh) 2023-08-11 2025-02-20 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
EP4658658A1 (en) * 2023-02-02 2025-12-10 Uppthera, Inc. Novel plk1 degradation inducing compound
CN118946561A (zh) * 2023-03-10 2024-11-12 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
TW202502750A (zh) 2023-06-08 2025-01-16 美商新銳思生物製藥股份有限公司 Smarca2之雙官能選擇性降解劑及其治療用途
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途
US20250197411A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN118724841B (zh) * 2024-06-14 2026-06-19 南通华祥医药科技有限公司 一种n-氨基哌啶二盐酸盐的制备方法
WO2026114368A1 (zh) * 2024-11-28 2026-06-04 西藏海思科制药有限公司 一种vav1靶向降解剂及其用途
WO2026114367A1 (zh) * 2024-11-28 2026-06-04 西藏海思科制药有限公司 Vav1靶向降解剂及其用途
WO2026114343A1 (zh) * 2024-11-29 2026-06-04 上海美悦生物科技发展有限公司 杂环化合物、及其药物组合物和用途
WO2026158584A1 (zh) * 2025-01-25 2026-07-30 杭州和正医药有限公司 多杂环类vav1降解分子衍生物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN106543185A (zh) * 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) * 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021061894A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010542B1 (en) * 2006-04-12 2012-01-25 Vertex Pharmaceuticals Incorporated 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridines as plk1 protein kinase inhibitors for the treatment of proliferative disorders
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CN101636399B (zh) 2007-03-22 2012-04-18 武田药品工业株式会社 可用作plk1抑制剂的取代的嘧啶并二氮杂*
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
EP4031247A1 (en) 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN106543185A (zh) * 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) * 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021061894A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230104076A1 (en) * 2020-03-27 2023-04-06 Uppthera PLK1 Selective Degradation Inducing Compound
US11833208B2 (en) * 2020-03-27 2023-12-05 Uppthera, Inc. PLK1 selective degradation inducing compound
JP2024530195A (ja) * 2021-08-10 2024-08-16 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
JP2024530495A (ja) * 2021-08-10 2024-08-21 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
WO2025036285A1 (zh) 2023-08-11 2025-02-20 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途

Also Published As

Publication number Publication date
JP2023540728A (ja) 2023-09-26
CN116322700B (zh) 2024-08-20
KR102604801B1 (ko) 2023-11-22
WO2023018237A1 (en) 2023-02-16
EP4157849A1 (en) 2023-04-05
EP4384521A4 (en) 2025-09-03
ECSP24010109A (es) 2024-05-31
KR20230024251A (ko) 2023-02-20
IL310678A (en) 2024-04-01
MX2024001774A (es) 2024-04-24
US20250114460A1 (en) 2025-04-10
KR20230024302A (ko) 2023-02-20
KR20230024250A (ko) 2023-02-20
KR20240060721A (ko) 2024-05-08
US11939334B2 (en) 2024-03-26
KR102604803B1 (ko) 2023-11-22
AU2022327025A1 (en) 2024-03-21
WO2023018238A1 (en) 2023-02-16
CO2024001256A2 (es) 2024-03-18
EP4384520A4 (en) 2025-09-03
EP4157850A4 (en) 2024-11-20
US20230219966A1 (en) 2023-07-13
CA3228601A1 (en) 2023-02-16
EP4384521A1 (en) 2024-06-19
EP4157850A1 (en) 2023-04-05
KR102662205B1 (ko) 2024-04-30
JP2024530195A (ja) 2024-08-16
PE20240894A1 (es) 2024-04-24
KR20230024267A (ko) 2023-02-20
US20250101025A1 (en) 2025-03-27
US20230242541A1 (en) 2023-08-03
CR20240120A (es) 2024-05-22
EP4157849A4 (en) 2024-12-11
WO2023017442A1 (en) 2023-02-16
KR102604802B1 (ko) 2023-11-22
CN116261458B (zh) 2024-05-24
WO2023018236A1 (en) 2023-02-16
JP2024530495A (ja) 2024-08-21
JP7555155B2 (ja) 2024-09-24
EP4384520A1 (en) 2024-06-19
CN116261458A (zh) 2023-06-13
CL2024000373A1 (es) 2024-07-19
CN116322700A (zh) 2023-06-23
JP7555156B2 (ja) 2024-09-24
JP2023540729A (ja) 2023-09-26
US11912710B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
WO2023018236A1 (en) Novel plk1 degradation inducing compound
WO2021194318A1 (en) Plk1 selective degradation inducing compound
WO2024147703A1 (ko) Shp2 억제제 및 이의 용도
WO2024123102A1 (ko) Kras g12d 저해제로서 신규한 3환 화합물 및 이의 용도
WO2024063576A1 (ko) Kras 저해 물질로서 신규한 퀴나졸린 화합물
WO2019078619A1 (en) HETEROCYCLIC COMPOUND FOR USE AS A PROTEIN KINASE INHIBITOR
AU2021242143A1 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
WO2022270994A1 (ko) 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
WO2021086077A1 (ko) 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020045941A1 (ko) 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2022114812A1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2017078352A1 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2022245085A1 (ko) 헤테로아릴 유도체 화합물 및 이의 용도
WO2024162746A1 (ko) Ikzf2를 분해하는 인돌 화합물 및 이의 용도
WO2024205311A1 (en) Substituted sultam compound derivatives and their pharmaceutical use
WO2022225238A1 (ko) 헤테로아릴 유도체 화합물 및 이의 용도
WO2023121413A1 (ko) 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
WO2024155112A1 (en) 2,4-dianilinopyrimidine-based aurora-a kinase selective degradation inducing compounds
WO2024162828A1 (en) Novel plk1 degradation inducing compound
WO2025239662A1 (ko) 분해 약물-항체 접합체용 plk1 분해 유도 화합물
WO2026106389A1 (ko) Nmt 억제제 및 이의 용도
WO2026024131A1 (ko) 디하이드로티오피라노피리미딘 화합물 및 이의 용도
WO2025188163A1 (ko) Sos1 억제제 및 이의 용도
WO2023229378A1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2025110815A1 (ko) CDK 억제제로서 이미다조[1,2-b]피리다진 계열의 신규 화합물 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22855632

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22855632

Country of ref document: EP

Kind code of ref document: A1